Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Nat Rev Clin Oncol

Retrieve available abstracts of 21 articles:
HTML format



Single Articles


    November 2024
  1. DRAGO J, Modi S
    Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
    Nat Rev Clin Oncol. 2024 Nov 6. doi: 10.1038/s41571-024-00963.
    PubMed    


  2. WAKS AG, Martinez-Saez O, Tarantino P, Braso-Maristany F, et al
    Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
    Nat Rev Clin Oncol. 2024;21:818-832.
    PubMed     Abstract available


    August 2024
  3. LLOYD MR, Jhaveri K, Kalinsky K, Bardia A, et al
    Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
    Nat Rev Clin Oncol. 2024 Aug 23. doi: 10.1038/s41571-024-00935.
    PubMed     Abstract available


  4. MARRA A, Chandarlapaty S, Modi S
    Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Nat Rev Clin Oncol. 2024 Aug 2. doi: 10.1038/s41571-024-00933.
    PubMed    


    July 2024
  5. YOON J, Oh DY
    HER2-targeted therapies beyond breast cancer - an update.
    Nat Rev Clin Oncol. 2024 Jul 22. doi: 10.1038/s41571-024-00924.
    PubMed     Abstract available


    June 2024
  6. KILLOCK D
    ALND can be safely omitted for patients with sentinel-node macrometastases.
    Nat Rev Clin Oncol. 2024;21:402.
    PubMed    


    May 2024
  7. DIECI MV, Guarneri V
    Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain.
    Nat Rev Clin Oncol. 2024 May 22. doi: 10.1038/s41571-024-00907.
    PubMed    


    April 2024
  8. SIDAWAY P
    KN046 shows tolerability and activity in TNBC.
    Nat Rev Clin Oncol. 2024;21:251.
    PubMed    


    March 2024
  9. KONTOS D
    The promise of AI in personalized breast cancer screening: are we there yet?
    Nat Rev Clin Oncol. 2024 Mar 12. doi: 10.1038/s41571-024-00877.
    PubMed    


    January 2024
  10. MARRA A, Chandarlapaty S, Modi S
    Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Nat Rev Clin Oncol. 2024 Jan 8. doi: 10.1038/s41571-023-00849.
    PubMed     Abstract available


    December 2023
  11. BERTON GIACHETTI PPM, Curigliano G
    Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Nat Rev Clin Oncol. 2023 Dec 19. doi: 10.1038/s41571-023-00854.
    PubMed    


  12. MORRISON L, Loibl S, Turner NC
    The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
    Nat Rev Clin Oncol. 2023 Dec 11. doi: 10.1038/s41571-023-00840.
    PubMed     Abstract available


    November 2023
  13. SIDAWAY P
    Sacituzumab govitecan improves OS in heavily pretreated patients.
    Nat Rev Clin Oncol. 2023;20:734.
    PubMed    


    October 2023
  14. ARECCO L, Lambertini M
    Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE.
    Nat Rev Clin Oncol. 2023;20:662-663.
    PubMed    


    July 2023
  15. SIDAWAY P
    T-DXd is effective after T-DM1.
    Nat Rev Clin Oncol. 2023;20:426.
    PubMed    


    February 2023
  16. O'LEARY B
    PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching.
    Nat Rev Clin Oncol. 2023;20:67-68.
    PubMed    


    October 2022
  17. AGOSTINETTO E, Gligorov J, Piccart M
    Systemic therapy for early-stage breast cancer: learning from the past to build the future.
    Nat Rev Clin Oncol. 2022 Oct 17. pii: 10.1038/s41571-022-00687.
    PubMed     Abstract available


    July 2022
  18. VASAN N, Cantley LC
    At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.
    Nat Rev Clin Oncol. 2022;19:471-485.
    PubMed     Abstract available


    April 2022
  19. SIDAWAY P
    Pembrolizumab improves EFS in TNBC.
    Nat Rev Clin Oncol. 2022;19:220.
    PubMed    


    March 2022
  20. SOUTHEY MC, Dugue PA
    Improving breast cancer risk prediction with epigenetic risk factors.
    Nat Rev Clin Oncol. 2022 Mar 29. pii: 10.1038/s41571-022-00622.
    PubMed    


    November 2021
  21. BIANCHINI G, De Angelis C, Licata L, Gianni L, et al
    Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
    Nat Rev Clin Oncol. 2021 Nov 9. pii: 10.1038/s41571-021-00565.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.